Delivery Order SPE2DB24D6038-SPE2DB24FELPN

Award Date 8/14/24
Potential Completion Date 8/15/24
Potential Value $1.6K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Medical Supply Chain division of the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $3,258.24, is a delivery order for the supply of Copaxone 40 mg/mL syringes, a specialty medication. The contract has a firm-fixed price pricing type and an ultimate completion date of July 26, 2024. This delivery order is part of a larger Indefinite Delivery Contract (IDC) between...
This federal contract award is for the delivery of COPAXONE 40 MG/ML syringes to the Defense Logistics Agency (DLA). The contract, valued at $1,849.20, was awarded to AmerisourceBergen Drug Corporation, a major pharmaceutical distributor. The award is a delivery order under a larger Indefinite Delivery Contract (IDC) between AmerisourceBergen and the DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, for the supply of a comprehensive range of medical commodities to...
This is a federal delivery order contract awarded by the Defense Logistics Agency (DLA) Troop Support Medical to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. The contract, valued at $2,897.78, is for the delivery of COPAXONE 40 MG/ML syringes. This award is part of a larger Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA, valued at $999,999,999 and running through November 2026. The IDC serves as a vehicle for providing a comprehensive range of...
The Defense Logistics Agency (DLA) awarded a $1,583.28 firm-fixed-price delivery order contract to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, for the supply of COPAXONE 40 MG/ML syringes. This award is part of a larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at up to $999,999,999 through December 2025, which enables the agency to efficiently procure a comprehensive range of medical commodities to support military treatment programs and...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,303.95 firm fixed-price delivery order is for Copaxone 20 mg/mL syringes, a specialty medication used to treat multiple sclerosis. The award falls under Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a comprehensive range of pharmaceutical...
This federal contract award to Amerisourcebergen Drug Corp's Corporate Office Division is for the delivery of COPAXONE 40 MG/ML SYRINGEML, a pharmaceutical product, to the Defense Logistics Agency (DLA). The contract, valued at $1,583.28, is a Delivery Order under a larger Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, worth up to $999,999,999.00 through December 31, 2025. This single-award IDC serves as the primary vehicle for Amerisourcebergen to provide a comprehensive...
This federal contract award is a delivery order with a firm fixed price of $1,627.62 issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor. The order is for Copaxone 20 mg/ml syringes, a specialty medication, with a period of performance through August 20, 2024. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,660.80 delivery order contract is for the supply of COPAXONE 40 MG/ML SYRINGEML, a pharmaceutical product. The contract is a firm-fixed price delivery order, with an ultimate completion date of June 9, 2025. There is no set-aside designation for this award. AmerisourceBergen Drug Corp holds a significant...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the delivery of COPAXONE 40 MG/ML SYRINGEML. The firm-fixed-price delivery order contract has a ceiling value of $2,122.56 and a completion date of June 12, 2025. The contract is not designated as a set-aside. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at $999,999,999.00,...
This is a federal contract award to Amerisourcebergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) for the supply of COPAXONE 40 MG/ML SYRINGEML. The contract is a Delivery Order with a Firm Fixed Price of $2,929.12 and an ultimate completion date of April 4, 2025. The contract is not associated with any set-aside designation. Amerisourcebergen Drug Corp holds a significant Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, valued at...
  • SPE2DB24D6038
    Indefinite Delivery Contract
  • SPE2DB24D6038-SPE2DB24FELPN
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, for the delivery of Copaxone 40 mg/ml syringes. The award, valued at $1,583.28, is a Delivery Order under an Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, potentially worth up to $999,999,999 through December 2025. This IDC enables DLA to procure a comprehensive range of medical commodities, including prescription drugs and medical supplies, to support military treatment programs and facilities worldwide. The contract does not have a set-aside designation and is expected to be completed by August 15, 2024.

Generated 11/13/24, 9:11 AM